← Leaderboards
Gary L. Johnson
National Jewish Health
$39,128,449
Attributed
$44,726,792
Total exposure
23
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,726,792 · 23
By mechanism
R01$21,005,955 · 9
U24$13,608,046 · 1
R37$3,671,357 · 1
P50$2,361,363 · 2
U54$1,386,555 · 1
U01$1,189,534 · 1
Top collaborators
- Jen Jen Yeh12 shared
- Lee M Graves5 shared
- Michael E. Berens4 shared
- Christopher Ryan Miller4 shared
Others in their field
Top investigators on “Phosphotransferases”
- David Heimbrook · Leidos Biomedical Research, Inc.$26,594,235
- Peter Karl Sorger · Massachusetts Institute Of Technology$20,231,592
- Lewis C Cantley · Beth Israel Deaconess Medical Center$19,866,259
- Richard L Huganir · Johns Hopkins University$18,390,405
- Fulton T Crews · University Of North Carolina Chapel Hill$17,915,277
- Ze'ev A Ronai · Mount Sinai School Of Medicine Of Cuny$17,898,296
Research focus
PhosphotransferasesBaseSignal TransductionResponseProteomicsTumorCellsPharmaceutical PreparationsPathway InteractionsMutationProteinsCell LineInhibitor/AntagonistInnovationResearch PersonnelClinical TrialsKinase InhibitorTissuesMalignant Breast NeoplasmReceptorTechnologyGenesNovel TherapeuticsMass Spectrum Analysis
Grant awards (113)
Targeted EGFR for basal subtype pancreatic cancer$639,879
R01 · FY2025 · CA
Targeted EGFR for basal subtype pancreatic cancer$639,879
R01 · FY2024 · CA
Illuminating Function of the Understudied Druggable Kinome$2,252,146
U24 · FY2022 · DK · contact PI
Project 4: Chromatin Remodeling Drives the Adaptive Resistance Response to Targeted Kinase Inhibition in Breast Cancer$338,043
P50 · FY2022 · CA · contact PI
Illuminating Function of the Understudied Druggable Kinome$2,251,844
U24 · FY2021 · DK · contact PI
Project 4: Chromatin Remodeling Drives the Adaptive Resistance Response to Targeted Kinase Inhibition in Breast Cancer$337,963
P50 · FY2021 · CA · contact PI
Illuminating Function of the Understudied Druggable Kinome$2,259,159
U24 · FY2020 · DK · contact PI
Tumor subtypes and therapy response in pancreatic cancer$824,656
R01 · FY2020 · CA
Project 4: Chromatin Remodeling Drives the Adaptive Resistance Response to Targeted Kinase Inhibition in Breast Cancer$333,543
P50 · FY2020 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$38,649
P30 · FY2020 · CA · contact PI
Illuminating Function of the Understudied Druggable Kinome$2,265,987
U24 · FY2019 · DK · contact PI
Tumor subtypes and therapy response in pancreatic cancer$799,917
R01 · FY2019 · CA
The adaptive kinome in pancreatic cancer$575,301
R01 · FY2019 · CA
Credentialing murine models for glioblastoma preclinical drug development$472,269
R01 · FY2019 · CA
Project 4: Chromatin Remodeling Drives the Adaptive Resistance Response to Targeted Kinase Inhibition in Breast Cancer$258,169
P50 · FY2019 · CA · contact PI
Credentialing murine models for glioblastoma preclinical drug development$133,154
R01 · FY2019 · CA
Molecular Therapeutics Research Program (Program 3)$37,461
P30 · FY2019 · CA · contact PI
Illuminating Function of the Understudied Druggable Kinome$2,270,717
U24 · FY2018 · DK · contact PI
Credentialing murine models for glioblastoma preclinical drug development$605,422
R01 · FY2018 · CA
The adaptive kinome in pancreatic cancer$593,093
R01 · FY2018 · CA
Tumor subtypes and therapy response in pancreatic cancer$591,406
R01 · FY2018 · CA
Project 4: Chromatin Remodeling Drives the Adaptive Resistance Response to Targeted Kinase Inhibition in Breast Cancer$363,561
P50 · FY2018 · CA · contact PI
Core A: Omics Core$215,189
U54 · FY2018 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$38,646
P30 · FY2018 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$2,968
P30 · FY2018 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$2,101
P30 · FY2018 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$1,366
P30 · FY2018 · CA · contact PI
Illuminating Function of the Understudied Druggable Kinome$2,308,193
U24 · FY2017 · DK · contact PI
Credentialing murine models for glioblastoma preclinical drug development$631,422
R01 · FY2017 · CA
Tumor subtypes and therapy response in pancreatic cancer$600,010
R01 · FY2017 · CA
The adaptive kinome in pancreatic cancer$593,093
R01 · FY2017 · CA
Core A: Omics Core$391,146
U54 · FY2017 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$37,914
P30 · FY2017 · CA · contact PI
Tumor subtypes and therapy response in pancreatic cancer$600,010
R01 · FY2016 · CA
The adaptive kinome in pancreatic cancer$570,696
R01 · FY2016 · CA
Activation and Regulation of the Understudied Kinome Using MIB/MS Technology$395,126
U01 · FY2016 · MH · contact PI
Core A: Omics Core$379,518
U54 · FY2016 · CA · contact PI
Molecular Therapeutics Research Program (Program 3)$38,144
P30 · FY2016 · CA · contact PI
The adaptive kinome in pancreatic cancer$573,723
R01 · FY2015 · CA
Core A: Omics Core$400,702
U54 · FY2015 · CA · contact PI
Activation and Regulation of the Understudied Kinome Using MIB/MS Technology$395,126
U01 · FY2015 · MH · contact PI
Function of Cerebral Cavernous Malformation Proteins$389,912
R01 · FY2015 · GM · contact PI
Kinome Reprogramming in Response to Targeted Kinase Inhibitors$276,873
R01 · FY2015 · GM · contact PI
Defining Kinome Activity for Novel Therapies in Triple Negative Breast Cancer$197,817
P50 · FY2015 · CA · contact PI
Molecular Therapeutics$173,389
P30 · FY2015 · CA · contact PI
Function of Cerebral Cavernous Malformation Proteins$494,342
R01 · FY2014 · GM · contact PI
Activation and Regulation of the Understudied Kinome Using MIB/MS Technology$399,282
U01 · FY2014 · MH · contact PI
Kinome Reprogramming in Response to Targeted Kinase Inhibitors$277,181
R01 · FY2014 · GM · contact PI
Defining Kinome Activity for Novel Therapies in Triple Negative Breast Cancer$168,933
P50 · FY2014 · CA · contact PI
Molecular Therapeutics$163,720
P30 · FY2014 · CA · contact PI
Function of Cerebral Cavernous Malformation Proteins$477,040
R01 · FY2013 · GM · contact PI
Kinome Reprogramming in Response to Targeted Kinase Inhibitors$267,756
R01 · FY2013 · GM · contact PI
Molecular Therapeutics$170,333
P30 · FY2013 · CA · contact PI
Defining Kinome Activity for Novel Therapies in Triple Negative Breast Cancer$168,165
P50 · FY2013 · CA · contact PI
Function of Cerebral Cavernous Malformation Proteins$26,985
R01 · FY2013 · GM · contact PI
Function of Cerebral Cavernous Malformation Proteins$391,740
R01 · FY2012 · GM · contact PI
Receptor Interaction with GTP-Regulatory Proteins$359,011
R01 · FY2012 · GM · contact PI
Kinome Reprogramming in Response to Targeted Kinase Inhibitors$278,929
R01 · FY2012 · GM · contact PI
Defining Kinome Activity for Novel Therapies in Triple Negative Breast Cancer$195,169
P50 · FY2012 · CA · contact PI
Molecular Therapeutics$187,411
P30 · FY2012 · CA · contact PI
Molecular Therapeutics$2,552
P30 · FY2012 · CA · contact PI
Receptor Interaction with GTP-Regulatory Proteins$359,011
R01 · FY2011 · GM · contact PI
Regulation of Sequential Protein Kinase Pathways$315,524
R01 · FY2011 · DK · contact PI
Function of MEKK3 and its osmosensing scaffold protein$311,372
R01 · FY2011 · GM · contact PI
Molecular Therapeutics$188,000
P30 · FY2011 · CA · contact PI
Receptor Interaction with GTP-Regulatory Proteins$362,637
R01 · FY2010 · GM · contact PI
Regulation of Sequential Protein Kinase Pathways$318,711
R01 · FY2010 · DK · contact PI
Function of MEKK3 and its osmosensing scaffold protein$314,517
R01 · FY2010 · GM · contact PI
Regulation of Sequential Protein Kinase Pathways$101,370
R01 · FY2010 · DK · contact PI
Receptor Interaction with GTP-Regulatory Proteins$365,578
R01 · FY2009 · GM · contact PI
Receptor Interaction with GTP-Regulatory Proteins$363,186
R01 · FY2009 · GM · contact PI
Regulation of Sequential Protein Kinase Pathways$321,930
R01 · FY2009 · DK · contact PI
Function of MEKK3 and its osmosensing scaffold protein$317,694
R01 · FY2009 · GM · contact PI
Function of MEKK3 and its osmosensing scaffold protein$103,812
R01 · FY2009 · GM · contact PI
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$420,330
R37 · FY2008 · GM · contact PI
Regulation of Sequential Protein Kinase Pathways$321,930
R01 · FY2008 · DK · contact PI
Function of MEKK3 and its osmosensing scaffold protein$316,714
R01 · FY2008 · GM · contact PI
Function of MEKK3 and its osmosensing scaffold protein$110,656
R01 · FY2008 · GM · contact PI
Defining Signal Network Plasticity$73,150
R24 · FY2008 · GM · contact PI
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$422,871
R37 · FY2007 · GM · contact PI
Regulation of Sequential Protein Kinase Pathways$328,500
R01 · FY2007 · DK · contact PI
Function of MEKK3 and its osmosensing scaffold protein$95,046
R01 · FY2007 · GM · contact PI
EFFICACY OF COORDINATED SUPPORTIVE CARE IN GYNECOLOGIC ONCOLOGY PATIENTS$812
M01 · FY2007 · RR · contact PI
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$425,489
R37 · FY2006 · GM · contact PI
Function of MEKK3 and its osmosensing scaffold protein$285,138
R01 · FY2006 · GM · contact PI
Inhibitor Screens for Five MAPK Kinase Kinases Important in Human Disease$182,500
R21 · FY2006 · NS · contact PI
EFFICACY OF COORDINATED SUPPORTIVE CARE IN GYNECOLOGIC ONCOLOGY PATIENTS$20,796
M01 · FY2006 · RR · contact PI
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$425,777
R37 · FY2005 · GM
Regulation of Sequential Protein Kinase Pathways$334,153
R01 · FY2005 · DK
Function of MEKK3 and its osmosensing scaffold protein$292,000
R01 · FY2005 · GM
EFFICACY OF COORDINATED SUPPORTIVE CARE IN GYNECOLOGIC ONCOLOGY PATIENTS$43,297
M01 · FY2005 · RR
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$416,115
R37 · FY2004 · GM
Regulation of Sequential Protein Kinase Pathways$324,876
R01 · FY2004 · DK
Function of MEKK3 and its osmosensing scaffold protein$292,000
R01 · FY2004 · GM
UNC Center for Nanosensing the Stressome (RMI)$73,000
PN1 · FY2004 · EY
Efficacy of Coordinated Supportive Care in Gynecologic Oncology Patients$27,773
M01 · FY2004 · RR
Regulation of Sequential Protein Kinase Pathways$315,672
R01 · FY2003 · DK
Function of MEKK3 and its osmosensing scaffold protein$292,000
R01 · FY2003 · GM
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$209,820
R37 · FY2003 · GM
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$176,092
R37 · FY2003 · GM
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$381,733
R37 · FY2002 · GM
Regulation of Sequential Protein Kinase Pathways$361,825
R01 · FY2002 · DK
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$370,702
R37 · FY2001 · GM
REGULATION OF SEQUENTIAL PROTEIN KINASE PATHWAYS$270,701
R01 · FY2001 · DK
NIH--EGF/NEU RECEPTOR SIGNAL TRANSDUCTION$245,703
R01 · FY2001 · DK
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$56,625
R37 · FY2001 · GM
REGULATION OF SEQUENTIAL PROTEIN KINASE PATHWAYS$15,100
R01 · FY2001 · DK
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$274,820
R37 · FY2000 · GM
NIH--EGF/NEU RECEPTOR SIGNAL TRANSDUCTION$239,204
R01 · FY2000 · DK
REGULATION OF SEQUENTIAL PROTEIN KINASE PATHWAYS$223,010
R01 · FY2000 · DK
RECEPTOR INTERACTION WITH GTP REGULATORY PROTEINS$90,983
R37 · FY2000 · GM
REGULATION OF SEQUENTIAL PROTEIN KINASE PATHWAYS$52,850
R01 · FY2000 · DK
REGULATION OF SEQUENTIAL PROTEIN KINASE PATHWAYS$49,836
R01 · FY2000 · DK